Taysha Gene Therapies, Inc. (TSHA) Gains Wells Fargo's Support on Rett Syndrome Program Progress [Yahoo! Finance]
Taysha Gene Therapies, Inc. (TSHA)
Company Research
Source: Yahoo! Finance
TheFly reported on January 5 that Wells Fargo raised its price target on TSHA to $11 from $8 and maintained an Overweight rating. The firm credited the anticipated 2026 outperformance to the ongoing advancements in its primary Rett syndrome research, which are bolstered by the FDA's approval of a favorable trial design last year. Separately, on January 6, Taysha Gene Therapies, Inc. (NASDAQ:TSHA) reported progress on its TSHA-102 Rett syndrome program. The first patient in the REVEAL pivotal phase was dosed in Q4 2025, and the FDA authorized the use of ASPIRE trial data in the proposed BLA. With updated safety and efficacy data from REVEAL Part A due in H1 2026, TSHA plans to complete dosing in both studies by Q2 2026. Taysha Gene Therapies, Inc. (NASDAQ:TSHA) is a clinical-stage biotechnology company that develops adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system, including Rett syndrome. While we acknowledge the pote
Show less
Read more
Impact Snapshot
Event Time:
TSHA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TSHA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TSHA alerts
High impacting Taysha Gene Therapies, Inc. news events
Weekly update
A roundup of the hottest topics
TSHA
News
- Here's What Analysts Are Saying About Taysha Gene Therapies (TSHA) [Yahoo! Finance]Yahoo! Finance
- Taysha Gene Therapies Inc. (TSHA): A Promising Biotech on Rett Syndrome Drug Prospects [Yahoo! Finance]Yahoo! Finance
- Taysha Gene Therapies (NASDAQ:TSHA) had its "strong-buy" rating reaffirmed by analysts at Raymond James Financial, Inc..MarketBeat
- Taysha Gene Therapies (NASDAQ:TSHA) had its "buy" rating reaffirmed by analysts at Chardan Capital. They now have a $12.00 price target on the stock.MarketBeat
- Taysha Gene Therapies Announces Progress Across TSHA-102 Pivotal Gene Therapy Program in Rett SyndromeGlobeNewswire
TSHA
Earnings
- 11/4/25 - In-Line
TSHA
Sec Filings
- 2/5/26 - Form SCHEDULE
- 2/4/26 - Form 144
- 2/4/26 - Form 144
- TSHA's page on the SEC website